Skip to main content

Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema

  • 2018-04-06
  • Pediatric Allergy and Immunology 29(3)
    • K. Wickens
    • C. Barthow
    • E. Mitchell
    • T. Stanley
    • G. Purdie
    • Judy Rowden
    • Janice Kang
    • Fiona Hood
    • L. V. D. van den Elsen
    • Elizabeth E Forbes-Blom
    • I. Franklin
    • Phillipa Barnes
    • P. Fitzharris
    • Robyn M. Maude
    • P. Stone
    • P. Abels
    • R. Murphy
    • J. Crane

Abstract

Background: In a randomized placebo-controlled trial, we previously found that the probiotic Lactobacillus rhamnosus HN001 (HN001) taken by mothers from 35 weeks of gestation until 6 months post-partum if breastfeeding and their child from birth to age 2 years halved the risk of eczema during the first 2 years of life. We aimed to test whether maternal supplementation alone is sufficient to reduce eczema and compare this to our previous study when both the mother and their child were supplemented.

Methods: In this 2-centre, parallel double-blind, randomized placebo-controlled trial, the same probiotic as in our previous study (HN001, 6 × 109 colony-forming units) was taken daily by mothers from 14-16 weeks of gestation till 6 months post-partum if breastfeeding, but was not given directly to the child. Women were recruited from the same study population as the first study, where they or their partner had a history of treated asthma, eczema or hay fever.

Results: Women were randomized to HN001 (N = 212) or placebo (N = 211). Maternal-only HN001 supplementation did not significantly reduce the prevalence of eczema, SCORAD ≥ 10, wheeze or atopic sensitization in the infant by 12 months. This contrasts with the mother and child intervention study, where HN001 was associated with reductions in eczema (hazard ratio (HR): 0.39, 95% CI 0.19-0.79, P = .009) and SCORAD (HR = 0.61, 95% 0.37-1.02). However, differences in the HN001 effect between studies were not significant. HN001 could not be detected in breastmilk from supplemented mothers, and breastmilk TGF-β/IgA profiles were unchanged.

Conclusion: Maternal probiotic supplementation without infant supplementation may not be effective for preventing infant eczema.

Keywords: Lactobacillus rhamnosus HN001; atopic sensitization; bacteria in breastmilk; breastmilk proteins; eczema; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus rhamnosus NH001Reduced IgE-Associated Eczema in InfantsNeutral
Small
Lactobacillus rhamnosus R0011Reduced Infant EczemaNeutral
Small
⬆ Back to top
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Receive updates about our products, services, sales, and special offers. Unsubscribe anytime. See our Privacy Policy for details on how we handle your information.

Join Our Community

Use support@pillser.com to get in touch.